Serum oncostatin M predicts mucosal healing in patients with inflammatory bowel diseases treated with anti-TNF, but not vedolizumab
Copyright © 2022 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved..
BACKGROUND: Oncostatin M was recently highlighted as a promising biomarker for therapeutic effectiveness in inflammatory bowel diseases (IBD), with particular regard for infliximab. The primary aim was to evaluate the ability of serum oncostatin M to predict endoscopic response to different drugs in IBD.
METHODS: We selected two different cohorts of patients with IBD, treated with anti-TNF (infliximab and adalimumab) or with vedolizumab. Therapeutic response was evaluated at week 54 in terms of mucosal healing. Serum oncostatin M and C-reactive protein were measured at baseline; fecal calprotectin was measured at baseline and after 14 weeks of treatment. We evaluated the association of these biomarkers with mucosal healing at week 54.
RESULTS: Among 66 patients treated with anti-TNFs and 68 treated with vedolizumab, 35 and 31 attained mucosal healing, respectively. Mucosal healing at 54 weeks was significantly associated with low oncostatin M levels at baseline in the anti-TNF cohort; the diagnostic accuracy of oncostatin M at baseline in predicting mucosal healing was 0.91 (95% CI 0.84 to 0.99) in the anti-TNF cohort and 0.56 (95% CI 0.43 to 0.70, P < 0.001) in the vedolizumab cohort. Mucosal healing was also associated with low fecal calprotectin levels at week 14 in both cohorts.
CONCLUSION: Our study suggests that serum oncostatin M is a drug-specific biomarker, since it could be used to predict therapeutic effectiveness to anti-TNFs but not to vedolizumab. Moreover, these results emphasize the utility of serum oncostatin M measurement in patients treated with anti-TNF.
| Errataetall: |
CommentOn: Inflamm Bowel Dis. 2021 Oct 18;27(10):1564-1575. - PMID 33624092 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
|---|---|
| Enthalten in: |
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver - 54(2022), 10 vom: 30. Okt., Seite 1367-1373 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bertani, Lorenzo [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 03.10.2022 Date Revised 27.12.2022 published: Print-Electronic CommentOn: Inflamm Bowel Dis. 2021 Oct 18;27(10):1564-1575. - PMID 33624092 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.dld.2022.03.008 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM33922956X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM33922956X | ||
| 003 | DE-627 | ||
| 005 | 20231226002429.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.dld.2022.03.008 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1130.xml |
| 035 | |a (DE-627)NLM33922956X | ||
| 035 | |a (NLM)35393259 | ||
| 035 | |a (PII)S1590-8658(22)00212-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bertani, Lorenzo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Serum oncostatin M predicts mucosal healing in patients with inflammatory bowel diseases treated with anti-TNF, but not vedolizumab |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.10.2022 | ||
| 500 | |a Date Revised 27.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: Inflamm Bowel Dis. 2021 Oct 18;27(10):1564-1575. - PMID 33624092 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved. | ||
| 520 | |a BACKGROUND: Oncostatin M was recently highlighted as a promising biomarker for therapeutic effectiveness in inflammatory bowel diseases (IBD), with particular regard for infliximab. The primary aim was to evaluate the ability of serum oncostatin M to predict endoscopic response to different drugs in IBD | ||
| 520 | |a METHODS: We selected two different cohorts of patients with IBD, treated with anti-TNF (infliximab and adalimumab) or with vedolizumab. Therapeutic response was evaluated at week 54 in terms of mucosal healing. Serum oncostatin M and C-reactive protein were measured at baseline; fecal calprotectin was measured at baseline and after 14 weeks of treatment. We evaluated the association of these biomarkers with mucosal healing at week 54 | ||
| 520 | |a RESULTS: Among 66 patients treated with anti-TNFs and 68 treated with vedolizumab, 35 and 31 attained mucosal healing, respectively. Mucosal healing at 54 weeks was significantly associated with low oncostatin M levels at baseline in the anti-TNF cohort; the diagnostic accuracy of oncostatin M at baseline in predicting mucosal healing was 0.91 (95% CI 0.84 to 0.99) in the anti-TNF cohort and 0.56 (95% CI 0.43 to 0.70, P < 0.001) in the vedolizumab cohort. Mucosal healing was also associated with low fecal calprotectin levels at week 14 in both cohorts | ||
| 520 | |a CONCLUSION: Our study suggests that serum oncostatin M is a drug-specific biomarker, since it could be used to predict therapeutic effectiveness to anti-TNFs but not to vedolizumab. Moreover, these results emphasize the utility of serum oncostatin M measurement in patients treated with anti-TNF | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Comment | |
| 650 | 4 | |a Biologics (IBD) | |
| 650 | 4 | |a Biomarkers | |
| 650 | 4 | |a Crohn's disease | |
| 650 | 4 | |a Inflammation | |
| 650 | 4 | |a Inflammatory bowel disease | |
| 650 | 4 | |a Ulcerative colitis | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Leukocyte L1 Antigen Complex |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor Inhibitors |2 NLM | |
| 650 | 7 | |a Oncostatin M |2 NLM | |
| 650 | 7 | |a 106956-32-5 |2 NLM | |
| 650 | 7 | |a C-Reactive Protein |2 NLM | |
| 650 | 7 | |a 9007-41-4 |2 NLM | |
| 650 | 7 | |a Infliximab |2 NLM | |
| 650 | 7 | |a B72HH48FLU |2 NLM | |
| 650 | 7 | |a Adalimumab |2 NLM | |
| 650 | 7 | |a FYS6T7F842 |2 NLM | |
| 700 | 1 | |a Barberio, Brigida |e verfasserin |4 aut | |
| 700 | 1 | |a Fornili, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Antonioli, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Zanzi, Federico |e verfasserin |4 aut | |
| 700 | 1 | |a Casadei, Cesare |e verfasserin |4 aut | |
| 700 | 1 | |a Benvenuti, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Facchin, Sonia |e verfasserin |4 aut | |
| 700 | 1 | |a D'Antongiovanni, Vanessa |e verfasserin |4 aut | |
| 700 | 1 | |a Lorenzon, Greta |e verfasserin |4 aut | |
| 700 | 1 | |a Ceccarelli, Linda |e verfasserin |4 aut | |
| 700 | 1 | |a Baglietto, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a de Bortoli, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Bellini, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Costa, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Savarino, Edoardo Vincenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Fornai, Matteo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver |d 2000 |g 54(2022), 10 vom: 30. Okt., Seite 1367-1373 |w (DE-627)NLM108968790 |x 1878-3562 |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:2022 |g number:10 |g day:30 |g month:10 |g pages:1367-1373 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.dld.2022.03.008 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 54 |j 2022 |e 10 |b 30 |c 10 |h 1367-1373 | ||